Biogen (BIIB) Fundamental Analysis: Revenue, Earnings & Valuation

7.79 / 10

Outperform

Fundamental analysis rates Biogen Outperform with a 7.8/10 score. Strong Asset‑MV and Profit‑MV drivers boost the view, while low Current‑assets turnover and modest Gross‑profit margin raise concerns. Overall, fundamentals are positive, supporting a strong investment case.

Analysis Checks(8/10)

Revenue-MV

Value0.02

Score3/3

Weight28.73%

1M Return9.51%

Inventory turnover ratio

Value1.04

Score2/3

Weight-1.06%

1M Return-0.56%

Gross profit margin (%)

Value75.69

Score0/3

Weight-8.41%

1M Return-5.42%

Profit-MV

Value0.98

Score2/3

Weight16.50%

1M Return6.36%

Income tax / Total profit (%)

Value16.94

Score3/3

Weight5.80%

1M Return2.26%

Current assets turnover ratio

Value1.20

Score1/3

Weight-0.36%

1M Return-0.17%

Fixed assets turnover ratio

Value3.17

Score2/3

Weight0.02%

1M Return0.01%

Cost of sales ratio (%)

Value24.31

Score2/3

Weight-6.76%

1M Return-3.62%

Asset-MV

Value-0.55

Score3/3

Weight49.38%

1M Return15.70%

Cash-MV

Value-0.01

Score2/3

Weight16.17%

1M Return6.19%

Is BIIB undervalued or overvalued?

BIIB scores 7.79/10 on fundamentals and holds a Discounted valuation at present. Backed by its 7.39% ROE, 13.07% net margin, 21.69 P/E ratio, 1.54 P/B ratio, and -21.23% earnings growth, these metrics solidify its Outperform investment rating.